ArticleWorld journal of clinical cases2024
Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis.
Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of enteral nutrition and parenteral nutrition in the management of inflammatory bowel disease: a bibliometric analysis (1999-2025).Frontiers in nutrition · 2026Pooled it
- Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis.Gut microbes · 2026Review
- Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Mirtazapine for the treatment of irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Current status of 5-aminosalicylic acid in Crohn's disease treatment: a nationwide survey and analysis of perspectives and practice patterns among inflammatory bowel disease physicians.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies.Pharmacogenomics and personalized medicine · 2025Review
- Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan.Journal of inflammation research · 2025Article
- Optimal Management of Patients with Moderate-to-Severe Inflammatory Bowel Disease.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of refractory ulcerative colitis (UC) and acute severe UC (ASUC) is challenging due to the lack of standardized approaches in cases resistant to multiple treatments. In this editorial, I investigate the efficacy and safety of Janus kinase inhibitors, particularly upadacitinib and tofacitinib, in controlling severe and refractory disease. I highlight a notable case report by Xu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.